Annette Matthies, Ph.D., joined Elicio Therapeutics as Chief Business Officer in January 2021. She brings nearly 20 years of biotech experience in corporate strategy, business development, new product planning, and private and public fund raising. Broadening Annette’s Ph.D. expertise in immunology, microbiology and virology, she has worked in the therapeutic areas of oncology and immuno-oncology (IO), inflammatory and autoimmune diseases, metabolic disease, and fibrosis.
Annette is an entrepreneur and passionate about building culture driven by her motivation to improve the lives of others. Most recently, Annette was Vice President of Corporate Development at eFFECTOR Therapeutics where she led business development activities. At Receptos (acquired by Celgene in an all-cash $7.2B purchase), Annette played an integral role in the company’s Initial Public Offering, follow-on offerings, and technology platform partnerships. She spearheaded the valuation assessment and indication prioritization for the MS and IBD lead asset ZEPOSIA® and metabolic early-stage pipeline. Annette joined Abbott Laboratories following the acquisition of Facet Biotech (a $450M all-cash purchase), in a post-acquisition integration position to transition new product planning practices to Abbott’s newly formed Global Strategy, Marketing and Services team. Prior to Abbott, Annette held positions of increasing responsibility in business development and market research at Facet Biotech and Biogen Idec.
Annette began her career as a strategy consultant in the Life Sciences practice of L.E.K. Consulting. Annette received her B.A., cum laude, in Biology from Augustana College. Annette received her Ph.D. in Immunology, Microbiology and Virology at Loyola University and completed a postdoctoral fellowship in bioengineering at the Swiss Federal Institute of Technology, ETH Zurich and EPFL.
In her free time, Annette enjoys sailing, power boating and racing cars. She is an avid meditator and yoga practitioner. Most of all, she loves to spend time with friends and family.